Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive ...

The latest update was submitted on June 24, 2025, indicating ongoing recruitment and progress. For investors, this study represents a significant development in Regeneron’s cardiovascular portfolio.

The overall sentiment of these big-money traders is split between 36% bullish and 31%, bearish. Out of all of the special options we uncovered, 10 are puts, for a total amount of $724,710, and 12 are ...

In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in ...

Regeneron’s treatment for age-related macular degeneration (AMD) Eylea and Eylea HD generated $5.9 billion in 2024 in the United States. Eylea sales rose just 1% YoY in 2024 as this blockbuster ...

Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement.

How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition Battle against Amgen is being closely watched by the biosimilar industry, lawmakers Adobe ...

Regeneron’s deal to acquire 23andMe is still subject to approval in the U.S. Bankruptcy Court for the Eastern District of Missouri. A hearing in the case was scheduled for June 17.